Fibrinogen–Thrombin–Fibrin polymer matrix

The fibrinogen–thrombin–fibrin polymer matrix is a complex protein structure formed during the final stage of the blood coagulation cascade [StatPearls: Physiology, Fibrinogen]. It is produced when the enzyme thrombin (Factor IIa) cleaves fibrinopeptides from the soluble plasma protein fibrinogen, allowing the resulting fibrin monomers to polymerize into an insoluble meshwork [StatPearls: Thrombin; UniProt: P02671]. This matrix serves as the primary structural scaffold for blood clots, providing mechanical stability to stop bleeding and a temporary framework for cellular infiltration during wound healing [StatPearls: Physiology, Fibrinogen; PubMed: PMID 11511036]. In clinical practice, this system is used as a therapeutic fibrin sealant (e.g., Tisseel) to control surgical bleeding and promote tissue adhesion [FDA: Tisseel Label]. Pathologically, the stabilization of this matrix is a key factor in thrombotic disorders, making it a critical target for fibrinolytic drugs like alteplase that dissolve clots and antifibrinolytic agents like tranexamic acid that prevent their premature degradation [StatPearls: Physiology, Fibrinogen; PubMed: PMID 11511036].

Other names

Fibrin sealantFibrin glueFibrin clotFibrin matrixHemostatic sealantFibrinogen-thrombin complex

Thrombolytic agents (e.g., alteplase) bind to the fibrin component of the matrix and convert trapped plasminogen into plasmin, which enzymatically cleaves the fibrin polymer into soluble fragments [StatPearls: Physiology, Fibrinogen]. Antifibrinolytics (e.g., tranexamic acid) competitively inhibit the activation of plasminogen, thereby stabilizing the fibrin matrix [PubMed: PMID 11511036]. Exogenous fibrin sealants mimic the final step of the coagulation cascade to provide immediate mechanical sealing and hemostasis [FDA: Tisseel Label].